NewAmsterdam Pharma Company N.V.

At the reported cash balance, the company has a multi‑quarter runway consistent with completing near‑term pivotal readouts without an immediate equity raise, reducing short‑term dilution risk. If cash funds key readouts, shareholders gain optionality from trial outcomes without immediate dilution; if runway shortens, the company will likely raise capital or cut programs, diluting shareholders and compressing value.

Sustainable, growing revenue depends causally on regulatory approval and payer acceptance of its late‑stage cardiometabolic therapy(ies); without approval/coverage, current product revenue is non‑recurring and cannot underwrite the business. Approval and reimbursement are prerequisites for converting R&D spending into recurring sales that justify a higher valuation; failure keeps the company dependent on capital markets.

If product sales scale materially, operating leverage should shrink losses because current large negative operating income reflects investment phase R&D and SG&A; revenues scaling are the causal path to converting losses to profitability. Realizing operating leverage converts R&D expense into future free cash flow and supports valuation expansion; if revenues never scale, losses will continue and destroy equity value.

Because operating cash flow is consistently negative, a major clinical or regulatory setback will causally force capital actions (dilutive financing, asset sales, program cuts) before revenue can offset burn. Setbacks will rapidly change the company’s financing needs and shareholder dilution outlook; avoiding such setbacks preserves optionality from late‑stage programs.